Letko Brosseau & Associates Inc. trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 1.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 343,632 shares of the company’s stock after selling 3,857 shares during the quarter. Letko Brosseau & Associates Inc.’s holdings in Merck & Co., Inc. were worth $49,933,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MRK. BlackRock Inc. raised its stake in shares of Merck & Co., Inc. by 0.5% during the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock valued at $29,169,479,000 after acquiring an additional 1,073,507 shares during the last quarter. State Street Corp lifted its holdings in shares of Merck & Co., Inc. by 0.9% during the second quarter. State Street Corp now owns 120,413,256 shares of the company’s stock worth $15,573,754,000 after purchasing an additional 1,087,583 shares during the period. Wellington Management Group LLP grew its stake in shares of Merck & Co., Inc. by 2.3% in the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock worth $11,083,033,000 after purchasing an additional 1,934,312 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Merck & Co., Inc. by 10.5% in the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after purchasing an additional 2,919,780 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Merck & Co., Inc. by 23.8% in the first quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock worth $1,858,938,000 after purchasing an additional 2,969,856 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
MRK has been the subject of a number of recent research reports. HSBC increased their price objective on Merck & Co., Inc. from $150.00 to $172.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Zacks Research downgraded Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a report on Monday, October 19th. Argus assumed coverage on Merck & Co., Inc. in a report on Tuesday, November 3rd. They set a “strong-buy” rating on the stock. Wolfe Research upped their price target on Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a research report on Tuesday, August 25th. Finally, Freedom Broker increased their price target on Merck & Co., Inc. from $125.00 to $140.00 and gave the company a “hold” rating in a research note on Monday, November 2nd. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $155.74.
Merck & Co., Inc. Stock Down 0.1%
Shares of Merck & Co., Inc. stock opened at $146.98 on Friday. Merck & Co., Inc. has a one year low of $90.90 and a one year high of $156.92. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.35 and a quick ratio of 1.14. The stock’s 50-day moving average is $146.25 and its 200 day moving average is $128.41. The firm has a market cap of $362.34 billion, a price-to-earnings ratio of 151.52, a PEG ratio of 6.75 and a beta of 0.13.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its earnings results on Thursday, October 29th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.09 by $0.40. The business had revenue of $18.09 billion during the quarter, compared to analysts’ expectations of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The firm’s revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the firm posted $2.58 earnings per share. Equities research analysts anticipate that Merck & Co., Inc. will post 2.82 EPS for the current year.
Merck & Co., Inc. News Roundup
These are some of the MRK news items that stood out recently:
- Positive Sentiment: Merck and Moderna plan to file their personalized cancer vaccine, intismeran, with Keytruda this year. The combination reduced the risk of melanoma recurrence or death by 42%, a potentially important growth opportunity if supported by upcoming data and regulatory review. Article: Merck’s Keytruda Combo Cut Melanoma Recurrence or Death Risk 42%. What the February 2 Report Has to Prove
- Positive Sentiment: Phase 2b results for efinopegdutide showed statistically significant MASH resolution without worsening fibrosis. The data add to investor optimism about Merck’s pipeline beyond Keytruda. Article: Merck (MRK) Could Be 7% Undervalued As MASH Trial Data Lifts Optimism
- Neutral Sentiment: Merck is scheduled to participate in the Jefferies Global Healthcare Conference in London. The appearance could provide investors with updates, but the announcement itself gives no new financial or clinical information. Article: Merck to Participate in the Jefferies Global Healthcare Conference in London
About Merck & Co., Inc.
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Read More
- Five stocks we like better than Merck & Co., Inc.
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
